These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24167183)

  • 21. Post-operative intensity-modulated radiotherapy for malignancies of the nasal cavity and paranasal sinuses.
    Dirix P; Nuyts S; Vanstraelen B; Nulens A; Hermans R; Jorissen M; Vander Poorten V; Van den Bogaert W
    Radiother Oncol; 2007 Dec; 85(3):385-91. PubMed ID: 17963908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.
    Dolezel M; Odrazka K; Vaculikova M; Vanasek J; Sefrova J; Paluska P; Zouhar M; Jansa J; Macingova Z; Jarosova L; Brodak M; Moravek P; Hartmann I
    Strahlenther Onkol; 2010 Apr; 186(4):197-202. PubMed ID: 20354663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
    Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
    Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure.
    Wiegner EA; Daly ME; Murphy JD; Abelson J; Chapman CH; Chung M; Yu Y; Colevas AD; Kaplan MJ; Fischbein N; Le QT; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):243-51. PubMed ID: 22019239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study.
    Huang J; Kong FF; Oei RW; Zhai RP; Hu CS; Ying HM
    Radiat Oncol; 2019 Feb; 14(1):31. PubMed ID: 30736809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies.
    Fan M; Kang JJ; Lee A; Fan D; Wang H; Kitpanit S; Fox P; Sine K; Mah D; McBride SM; Tsai CJ; Riaz N; Dunn LA; Sherman EJ; Michel L; Singh B; Ganly I; Wong RJ; Boyle JO; Cohen MA; Lee NY
    Cancer; 2020 Jan; 126(9):1905-1916. PubMed ID: 32097507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results.
    Shen Q; Ma X; Hu W; Chen L; Huang J; Guo Y
    Radiat Oncol; 2013 Jun; 8():152. PubMed ID: 23800149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study.
    Badakhshi H; Gruen A; Graf R; Boehmer D; Budach V
    Gastric Cancer; 2014; 17(3):537-41. PubMed ID: 24122094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiotherapy as Part of Treatment Strategies in Nasal Cavity and Paranasal Sinus Malignancies.
    Owin N; Elsayad K; Rolf D; Haverkamp U; Suwelack D; Tschakert R; Berssenbrugge H; Kleinheinz J; Rudack C; Eich HT
    Anticancer Res; 2021 Mar; 41(3):1587-1592. PubMed ID: 33788753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dose distributions of proton beam therapy for hepatocellular carcinoma: a comparative study of treatment planning with 3D-conformal radiation therapy or intensity-modulated radiation therapy].
    Li JM; Yu JM; Liu SW; Chen Q; Mu XK; Jiang QA; Zhao MH; Zhang JG
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(45):3201-6. PubMed ID: 20193534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tomotherapy as a neoadjuvant treatment for locally advanced esophageal cancer might increase bone marrow toxicity in comparison with intensity-modulated radiotherapy and volumetric-modulated arc therapy.
    Wang Y; Xiao Q; Zeng B; Ni Q; Liu X; Liu X; Tian L; Sheng C; Peng L; Wang H
    Med Dosim; 2020 Spring; 45(1):e6-e12. PubMed ID: 31176536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
    Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer.
    Nichols RC; Huh SN; Prado KL; Yi BY; Sharma NK; Ho MW; Hoppe BS; Mendenhall NP; Li Z; Regine WF
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):158-63. PubMed ID: 22245197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update.
    Madani I; Bonte K; Vakaet L; Boterberg T; De Neve W
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):424-32. PubMed ID: 18755554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.
    Deville C; Both S; Bui V; Hwang WT; Tan KS; Schaer M; Tochner Z; Vapiwala N
    Radiat Oncol; 2012 May; 7():76. PubMed ID: 22621764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volumetric-modulated arc therapy vs. c-IMRT in esophageal cancer: a treatment planning comparison.
    Yin L; Wu H; Gong J; Geng JH; Jiang F; Shi AH; Yu R; Li YH; Han SK; Xu B; Zhu GY
    World J Gastroenterol; 2012 Oct; 18(37):5266-75. PubMed ID: 23066322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
    DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
    Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer.
    Verma J; Sulman EP; Jhingran A; Tucker SL; Rauch GM; Eifel PJ; Klopp AH
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):357-62. PubMed ID: 24411609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.